This category covers biotechnology and pharmaceutical companies developing mitochondrial-targeted neuroprotection therapies for Parkinson's disease. These approaches address the fundamental mitochondrial dysfunction that is a central pathological feature in PD, including Complex I deficiency, impaired mitophagy, oxidative stress, and defective mitochondrial dynamics.
The rationale for mitochondrial-targeted therapies in PD is strong, supported by both genetic evidence (PINK1, PARKIN, DJ-1 mutations causing familial PD) and environmental evidence (MPTP, rotenone, pesticides causing mitochondrial Complex I inhibition and PD-like syndromes).
¶ Vandria SA
- Focus: Mitochondrial quality control and mitophagy induction
- Lead Candidate: VNA-100
- Indication: Parkinson's disease
- Stage: Preclinical/IND-enabling
- Mechanism: Mitophagy inducer targeting the PINK1-PARKIN pathway
- Notes: Swiss-based company with dual programs in AD (VNA-318) and PD (VNA-100)
- Page: Vandria SA
- Focus: Mitochondrial antioxidants
- Lead Candidate: NMT-101
- Indication: Parkinson's disease
- Stage: Phase 2
- Mechanism: Mitochondria-targeted nitroxide compound (TPP moiety) for selective ROS scavenging
- Notes: Based in Boston, Series C funded in 2025
- Page: NeuroMito Therapeutics
- Focus: Catalytic nanotherapeutic approach
- Lead Candidate: CNM-Au8
- Indication: Parkinson's disease (and ALS)
- Stage: Phase 2
- Mechanism: Gold nanocrystals catalyze redox reactions to support mitochondrial function and reduce oxidative stress
- Notes: Oral bioavailability, crosses blood-brain barrier
- Page: Clene Nanomedicine
- Focus: Mitochondrial protection
- Lead Candidate: NP-101
- Indication: Parkinson's disease
- Stage: Phase 1
- Mechanism: Mitochondria-targeted therapeutic
- Page: Napa Therapeutics
- Focus: Mitochondrial protectants
- Lead Candidate: MT-101
- Indication: Neurodegeneration (including PD)
- Stage: Preclinical
- Mechanism: CoQ10-based mitochondrial protectant with ubiquinone moiety for direct ROS scavenging
- Page: Mitothera
Companies developing antioxidants specifically targeted to mitochondria using lipophilic cations (TPP - triphenylphosphonium) that accumulate in the mitochondrial matrix due to the mitochondrial membrane potential:
- NeuroMito Therapeutics (NMT-101): TPP-nitroxide conjugate
- MitoQ (not a company): Mitoquinone - TPP-ubiquinone
- SS-31 (elamipretide): Mitochondria-targeted peptide
Companies targeting the PINK1-PARKIN pathway to enhance clearance of damaged mitochondria:
- Vandria (VNA-100): Small molecule mitophagy activator
Companies using catalytic nanomaterials to support mitochondrial redox reactions:
- Clene Nanomedicine (CNM-Au8): Gold nanocrystals
¶ CoQ10 Analogs and Precursors
Companies developing CoQ10 analogues for Complex I support:
- Mitothera (MT-101): Ubiquinone-based mitochondrial protectant
- Various nutraceutical companies
| Company |
Drug |
Mechanism |
Phase |
Status |
| NeuroMito |
NMT-101 |
Mitochondrial antioxidant |
Phase 2 |
Active |
| Clene |
CNM-Au8 |
Catalytic antioxidant |
Phase 2 |
Active |
| Napa |
NP-101 |
Mitochondria protectant |
Phase 1 |
Active |
| Vandria |
VNA-100 |
Mitophagy inducer |
Preclinical |
IND-enabling |
| Mitothera |
MT-101 |
CoQ10 analog |
Preclinical |
Research |
Mitochondrial dysfunction is one of the most consistent pathological findings in Parkinson's disease:
- Complex I deficiency: Observed in substantia nigra of sporadic PD patients
- Genetic evidence: PINK1, PARKIN, DJ-1 mutations cause familial PD through mitophagy defects
- Environmental evidence: MPTP, rotenone cause PD-like syndromes via Complex I inhibition
- Oxidative stress: Elevated ROS, reduced glutathione, increased lipid peroxidation
Mitochondrial-targeted approaches offer several advantages:
- Direct delivery: TPP-based compounds accumulate >100-fold in mitochondria
- Mechanism specificity: Target the precise cellular compartment affected in PD
- Disease modification potential: Address upstream pathology rather than symptoms
- Biomarker potential: Mitochondrial function can be monitored via CSF biomarkers